Latest Pharma Insights
GLP-1, Prevention And Wastewater Bills: Reflections On The 62nd AESGP Annual Meeting
Following three packed days at the AESGP’s Annual Meeting in Berlin, HBW Insight's David Ridley shares his thoughts on the meeting and the issues most preoccupying those working in Europe’s consumer health industry.
HBW Insight - June 23, 2026
Following three packed days at the AESGP’s Annual Meeting in Berlin, HBW Insight's David Ridley shares his thoughts on the meeting and the issues most preoccupying those working in Europe’s consumer health industry.
HBW Insight - June 23, 2026
Corxel’s Obesity Pill Stands Out On Tolerability In Phase II
The US-China company is looking to challenge Foundayo and other weight loss pills with CX11 and its improved tolerability, with encouraging Phase II results
Scrip - June 23, 2026
The US-China company is looking to challenge Foundayo and other weight loss pills with CX11 and its improved tolerability, with encouraging Phase II results
Scrip - June 23, 2026
Definium Proposes $500m Offering Following Phase III MDD Win For DT120
The proposed offering could help advance Definium's pipeline and support a potential launch for DT120.
Scrip - June 23, 2026
The proposed offering could help advance Definium's pipeline and support a potential launch for DT120.
Scrip - June 23, 2026
Abiomed’s Impella Safety Actions Mount As FDA Flags Another Class I Controller Correction
The latest FDA Class I correction for Abiomed’s Automated Impella Controllers is over a software error that can stop the heart pump for up to 75 seconds — the newest in a run of safety actions on J&J's Impella franchise, with deaths and injuries reported.
Medtech Insight - June 23, 2026
The latest FDA Class I correction for Abiomed’s Automated Impella Controllers is over a software error that can stop the heart pump for up to 75 seconds — the newest in a run of safety actions on J&J's Impella franchise, with deaths and injuries reported.
Medtech Insight - June 23, 2026
First Patients Treated With Beximco’s Generic Version Of Trikafta
At $12,750 per year versus $370,000 for Trikafta, Beximco's generic is now in patients' hands, with orders placed from June scheduled for November distribution via a single authorized global supplier.
Generics Bulletin - June 23, 2026
At $12,750 per year versus $370,000 for Trikafta, Beximco's generic is now in patients' hands, with orders placed from June scheduled for November distribution via a single authorized global supplier.
Generics Bulletin - June 23, 2026
Pfizer Faces Lung Cancer Setback For Key Seagen ADC Sigvotatug Vedotin
Pfizer's SigVie-002 trial miss leaves sigvotatug vedotin's future riding on first-line combination data.
Scrip - June 23, 2026
Pfizer's SigVie-002 trial miss leaves sigvotatug vedotin's future riding on first-line combination data.
Scrip - June 23, 2026
Henlius And Organon Deepen Canada’s Denosumab Biosimilar Race
Henlius and Organon have launched Bildyos and Tuzemty in Canada, adding two more denosumab biosimilars to an increasingly crowded market while expanding Organon’s bone-care and oncology biosimilars portfolio.
Generics Bulletin - June 23, 2026
Henlius and Organon have launched Bildyos and Tuzemty in Canada, adding two more denosumab biosimilars to an increasingly crowded market while expanding Organon’s bone-care and oncology biosimilars portfolio.
Generics Bulletin - June 23, 2026
Pharma Sales To Top $2 Trillion As The Big Drug Era Beds In
Powered by the obesity gold rush and led by Eli Lilly's record-breaking tirzepatide, Evaluate's 2026 World Preview shows that pharma is set to break the new sales barriers in the coming years.
Scrip - June 23, 2026
Powered by the obesity gold rush and led by Eli Lilly's record-breaking tirzepatide, Evaluate's 2026 World Preview shows that pharma is set to break the new sales barriers in the coming years.
Scrip - June 23, 2026
Sanofi Plans ‘Careful’ Launch For MS Drug Cenrifki
The oral BTK inhibitor has just got the nod in the EU for non-relapsing secondary progressive multiple sclerosis after a rejection from the US FDA at the end of 2026.
Scrip - June 23, 2026
The oral BTK inhibitor has just got the nod in the EU for non-relapsing secondary progressive multiple sclerosis after a rejection from the US FDA at the end of 2026.
Scrip - June 23, 2026
India Considers Letting Hospitals Bypass Import Rules For High-End Medical Equipment, Faces Pushback
India's drug regulator has proposed letting hospitals import high-end medical equipment directly — bypassing the licensing framework every other importer must follow. Domestic manufacturers say it contradicts Make in India, creates safety gaps, and favors foreign OEMs over local industry.
Medtech Insight - June 23, 2026
India's drug regulator has proposed letting hospitals import high-end medical equipment directly — bypassing the licensing framework every other importer must follow. Domestic manufacturers say it contradicts Make in India, creates safety gaps, and favors foreign OEMs over local industry.
Medtech Insight - June 23, 2026
Stock Watch: Qualifying A Functional Cure For Hepatitis B
While many companies have tried and failed to achieve a functional cure in chronically infected hepatitis B patients, GSK’s recent announcement suggests that one may finally be close. But bepirovirsen’s sales potential will depend on several factors.
Scrip - June 23, 2026
While many companies have tried and failed to achieve a functional cure in chronically infected hepatitis B patients, GSK’s recent announcement suggests that one may finally be close. But bepirovirsen’s sales potential will depend on several factors.
Scrip - June 23, 2026
Adalvo Adds HIV Asset To Expanding Day-One Pipeline
Adalvo’s European DCP filing for generic dolutegravir adds an HIV asset to a growing slate of complex generics, value-added medicines and day-one launch programs spanning antivirals, oncology, dermatology and rare diseases.
Generics Bulletin - June 23, 2026
Adalvo’s European DCP filing for generic dolutegravir adds an HIV asset to a growing slate of complex generics, value-added medicines and day-one launch programs spanning antivirals, oncology, dermatology and rare diseases.
Generics Bulletin - June 23, 2026
J&J Widens Golimumab Patent Fight With Alvotech Lawsuit
Janssen’s latest suit adds Alvotech to the US golimumab patent fight, threatening AVT05’s planned December approval as biosimilar competition builds around the $1.1bn Simponi franchise.
Generics Bulletin - June 23, 2026
Janssen’s latest suit adds Alvotech to the US golimumab patent fight, threatening AVT05’s planned December approval as biosimilar competition builds around the $1.1bn Simponi franchise.
Generics Bulletin - June 23, 2026
From Pluvicto to Kisunla, Big Pharma Recasting India Bet?
Big pharma appears to be targeting “pockets of commercial viability” for premium, cutting-edge therapies in India, where even thin sales volumes can punch above their weight in terms of topline contribution. Pricing innovation could be put to test, though.
Scrip - June 23, 2026
Big pharma appears to be targeting “pockets of commercial viability” for premium, cutting-edge therapies in India, where even thin sales volumes can punch above their weight in terms of topline contribution. Pricing innovation could be put to test, though.
Scrip - June 23, 2026
UK MHRA’s Global Device Ambitions Extend To Two-Way Reliance
Rob Reid, the MHRA’s deputy director for innovative devices, gave a snapshot of the agency’s current device regulatory agenda to Medtech Insight.
Medtech Insight - June 23, 2026
Rob Reid, the MHRA’s deputy director for innovative devices, gave a snapshot of the agency’s current device regulatory agenda to Medtech Insight.
Medtech Insight - June 23, 2026
AI Center Stage For Biomed Israel Start-Up Winners 2026
Four innovators, Protai, BAIBYS, caVos Biotherapeutics and Starget Pharma, won Biomed Israel’s 2026 start-up showcase competition.
In Vivo - June 23, 2026
Four innovators, Protai, BAIBYS, caVos Biotherapeutics and Starget Pharma, won Biomed Israel’s 2026 start-up showcase competition.
In Vivo - June 23, 2026
EU Wastewater: OTC And Cosmetics Industries Welcome Parliament Call For EPR Pause
European consumer health and cosmetics industries have welcomed a non-binding European Parliament vote urging the Commission to pause the Urban Wastewater Treatment Directive's extended producer responsibility scheme and re-examine the evidence behind it.
HBW Insight - June 23, 2026
European consumer health and cosmetics industries have welcomed a non-binding European Parliament vote urging the Commission to pause the Urban Wastewater Treatment Directive's extended producer responsibility scheme and re-examine the evidence behind it.
HBW Insight - June 23, 2026
Doctors Rank ChatGPT Health Answers Higher Than Physician Responses, OpenAI Claims
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
Medtech Insight - June 23, 2026
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
Medtech Insight - June 23, 2026
Pharma World Preview 2026: The Formula And Its Fractures
Pharma is generating bigger returns from smaller bets. Evaluate’s World Preview 2026 shows an industry that has found its formula — and is squeezing it hard. The question is how long it holds.
In Vivo - June 23, 2026
Pharma is generating bigger returns from smaller bets. Evaluate’s World Preview 2026 shows an industry that has found its formula — and is squeezing it hard. The question is how long it holds.
In Vivo - June 23, 2026
CARsgen’s Satri-Cel Gains World-First Approval In Gastric Cancer
China's CARsgen obtains domestic approval for its anti-Claudin 18.2 CAR-T therapy satri-cel for heavily pretreated gastric or gastroesophageal junction cancer with limited treatment options and poor prognosis, but its price means limited commercial opportunities.
Scrip - June 23, 2026
China's CARsgen obtains domestic approval for its anti-Claudin 18.2 CAR-T therapy satri-cel for heavily pretreated gastric or gastroesophageal junction cancer with limited treatment options and poor prognosis, but its price means limited commercial opportunities.
Scrip - June 23, 2026
Insilico, SK Biopharm’s $2.5bn AI Drug Discovery Pact Targets Neuroimmune Disorders
Insilico Medicine and SK Biopharmaceuticals sign a CNS-focused, AI-powered drug discovery collaboration worth up to $2.5bn, pairing the former's tech platform with the Korean company's clinical and commercial capabilities.
Scrip - June 23, 2026
Insilico Medicine and SK Biopharmaceuticals sign a CNS-focused, AI-powered drug discovery collaboration worth up to $2.5bn, pairing the former's tech platform with the Korean company's clinical and commercial capabilities.
Scrip - June 23, 2026
BIO Notebook: Regulatory Flexibility By Any Other Name
The opening day of the BIO International Convention featured a debate over the term regulatory flexibility, updates on the IPO environment and a frank assessment of biotech's progress with AI.
Scrip - June 23, 2026
The opening day of the BIO International Convention featured a debate over the term regulatory flexibility, updates on the IPO environment and a frank assessment of biotech's progress with AI.
Scrip - June 23, 2026
Corxel’s Obesity Pill Stands Out On Tolerability In Phase II
The US-China company is looking to challenge Foundayo and other weight loss pills with CX11 and its improved tolerability, with encouraging Phase II results
Scrip - June 23, 2026
The US-China company is looking to challenge Foundayo and other weight loss pills with CX11 and its improved tolerability, with encouraging Phase II results
Scrip - June 23, 2026
Definium Proposes $500m Offering Following Phase III MDD Win For DT120
The proposed offering could help advance Definium's pipeline and support a potential launch for DT120.
Scrip - June 23, 2026
The proposed offering could help advance Definium's pipeline and support a potential launch for DT120.
Scrip - June 23, 2026
Pfizer Faces Lung Cancer Setback For Key Seagen ADC Sigvotatug Vedotin
Pfizer's SigVie-002 trial miss leaves sigvotatug vedotin's future riding on first-line combination data.
Scrip - June 23, 2026
Pfizer's SigVie-002 trial miss leaves sigvotatug vedotin's future riding on first-line combination data.
Scrip - June 23, 2026
Pharma Sales To Top $2 Trillion As The Big Drug Era Beds In
Powered by the obesity gold rush and led by Eli Lilly's record-breaking tirzepatide, Evaluate's 2026 World Preview shows that pharma is set to break the new sales barriers in the coming years.
Scrip - June 23, 2026
Powered by the obesity gold rush and led by Eli Lilly's record-breaking tirzepatide, Evaluate's 2026 World Preview shows that pharma is set to break the new sales barriers in the coming years.
Scrip - June 23, 2026
Sanofi Plans ‘Careful’ Launch For MS Drug Cenrifki
The oral BTK inhibitor has just got the nod in the EU for non-relapsing secondary progressive multiple sclerosis after a rejection from the US FDA at the end of 2026.
Scrip - June 23, 2026
The oral BTK inhibitor has just got the nod in the EU for non-relapsing secondary progressive multiple sclerosis after a rejection from the US FDA at the end of 2026.
Scrip - June 23, 2026
Stock Watch: Qualifying A Functional Cure For Hepatitis B
While many companies have tried and failed to achieve a functional cure in chronically infected hepatitis B patients, GSK’s recent announcement suggests that one may finally be close. But bepirovirsen’s sales potential will depend on several factors.
Scrip - June 23, 2026
While many companies have tried and failed to achieve a functional cure in chronically infected hepatitis B patients, GSK’s recent announcement suggests that one may finally be close. But bepirovirsen’s sales potential will depend on several factors.
Scrip - June 23, 2026
From Pluvicto to Kisunla, Big Pharma Recasting India Bet?
Big pharma appears to be targeting “pockets of commercial viability” for premium, cutting-edge therapies in India, where even thin sales volumes can punch above their weight in terms of topline contribution. Pricing innovation could be put to test, though.
Scrip - June 23, 2026
Big pharma appears to be targeting “pockets of commercial viability” for premium, cutting-edge therapies in India, where even thin sales volumes can punch above their weight in terms of topline contribution. Pricing innovation could be put to test, though.
Scrip - June 23, 2026
CARsgen’s Satri-Cel Gains World-First Approval In Gastric Cancer
China's CARsgen obtains domestic approval for its anti-Claudin 18.2 CAR-T therapy satri-cel for heavily pretreated gastric or gastroesophageal junction cancer with limited treatment options and poor prognosis, but its price means limited commercial opportunities.
Scrip - June 23, 2026
China's CARsgen obtains domestic approval for its anti-Claudin 18.2 CAR-T therapy satri-cel for heavily pretreated gastric or gastroesophageal junction cancer with limited treatment options and poor prognosis, but its price means limited commercial opportunities.
Scrip - June 23, 2026
Insilico, SK Biopharm’s $2.5bn AI Drug Discovery Pact Targets Neuroimmune Disorders
Insilico Medicine and SK Biopharmaceuticals sign a CNS-focused, AI-powered drug discovery collaboration worth up to $2.5bn, pairing the former's tech platform with the Korean company's clinical and commercial capabilities.
Scrip - June 23, 2026
Insilico Medicine and SK Biopharmaceuticals sign a CNS-focused, AI-powered drug discovery collaboration worth up to $2.5bn, pairing the former's tech platform with the Korean company's clinical and commercial capabilities.
Scrip - June 23, 2026
BIO Notebook: Regulatory Flexibility By Any Other Name
The opening day of the BIO International Convention featured a debate over the term regulatory flexibility, updates on the IPO environment and a frank assessment of biotech's progress with AI.
Scrip - June 23, 2026
The opening day of the BIO International Convention featured a debate over the term regulatory flexibility, updates on the IPO environment and a frank assessment of biotech's progress with AI.
Scrip - June 23, 2026
Abiomed’s Impella Safety Actions Mount As FDA Flags Another Class I Controller Correction
The latest FDA Class I correction for Abiomed’s Automated Impella Controllers is over a software error that can stop the heart pump for up to 75 seconds — the newest in a run of safety actions on J&J's Impella franchise, with deaths and injuries reported.
Medtech Insight - June 23, 2026
The latest FDA Class I correction for Abiomed’s Automated Impella Controllers is over a software error that can stop the heart pump for up to 75 seconds — the newest in a run of safety actions on J&J's Impella franchise, with deaths and injuries reported.
Medtech Insight - June 23, 2026
India Considers Letting Hospitals Bypass Import Rules For High-End Medical Equipment, Faces Pushback
India's drug regulator has proposed letting hospitals import high-end medical equipment directly — bypassing the licensing framework every other importer must follow. Domestic manufacturers say it contradicts Make in India, creates safety gaps, and favors foreign OEMs over local industry.
Medtech Insight - June 23, 2026
India's drug regulator has proposed letting hospitals import high-end medical equipment directly — bypassing the licensing framework every other importer must follow. Domestic manufacturers say it contradicts Make in India, creates safety gaps, and favors foreign OEMs over local industry.
Medtech Insight - June 23, 2026
UK MHRA’s Global Device Ambitions Extend To Two-Way Reliance
Rob Reid, the MHRA’s deputy director for innovative devices, gave a snapshot of the agency’s current device regulatory agenda to Medtech Insight.
Medtech Insight - June 23, 2026
Rob Reid, the MHRA’s deputy director for innovative devices, gave a snapshot of the agency’s current device regulatory agenda to Medtech Insight.
Medtech Insight - June 23, 2026
Doctors Rank ChatGPT Health Answers Higher Than Physician Responses, OpenAI Claims
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
Medtech Insight - June 23, 2026
Physicians have reviewed 700,000 AI responses to optimize health answers for GPT-5.5 Instant, OpenAI said.
Medtech Insight - June 23, 2026
GLP-1, Prevention And Wastewater Bills: Reflections On The 62nd AESGP Annual Meeting
Following three packed days at the AESGP’s Annual Meeting in Berlin, HBW Insight's David Ridley shares his thoughts on the meeting and the issues most preoccupying those working in Europe’s consumer health industry.
HBW Insight - June 23, 2026
Following three packed days at the AESGP’s Annual Meeting in Berlin, HBW Insight's David Ridley shares his thoughts on the meeting and the issues most preoccupying those working in Europe’s consumer health industry.
HBW Insight - June 23, 2026
EU Wastewater: OTC And Cosmetics Industries Welcome Parliament Call For EPR Pause
European consumer health and cosmetics industries have welcomed a non-binding European Parliament vote urging the Commission to pause the Urban Wastewater Treatment Directive's extended producer responsibility scheme and re-examine the evidence behind it.
HBW Insight - June 23, 2026
European consumer health and cosmetics industries have welcomed a non-binding European Parliament vote urging the Commission to pause the Urban Wastewater Treatment Directive's extended producer responsibility scheme and re-examine the evidence behind it.
HBW Insight - June 23, 2026
First Patients Treated With Beximco’s Generic Version Of Trikafta
At $12,750 per year versus $370,000 for Trikafta, Beximco's generic is now in patients' hands, with orders placed from June scheduled for November distribution via a single authorized global supplier.
Generics Bulletin - June 23, 2026
At $12,750 per year versus $370,000 for Trikafta, Beximco's generic is now in patients' hands, with orders placed from June scheduled for November distribution via a single authorized global supplier.
Generics Bulletin - June 23, 2026
Henlius And Organon Deepen Canada’s Denosumab Biosimilar Race
Henlius and Organon have launched Bildyos and Tuzemty in Canada, adding two more denosumab biosimilars to an increasingly crowded market while expanding Organon’s bone-care and oncology biosimilars portfolio.
Generics Bulletin - June 23, 2026
Henlius and Organon have launched Bildyos and Tuzemty in Canada, adding two more denosumab biosimilars to an increasingly crowded market while expanding Organon’s bone-care and oncology biosimilars portfolio.
Generics Bulletin - June 23, 2026
Adalvo Adds HIV Asset To Expanding Day-One Pipeline
Adalvo’s European DCP filing for generic dolutegravir adds an HIV asset to a growing slate of complex generics, value-added medicines and day-one launch programs spanning antivirals, oncology, dermatology and rare diseases.
Generics Bulletin - June 23, 2026
Adalvo’s European DCP filing for generic dolutegravir adds an HIV asset to a growing slate of complex generics, value-added medicines and day-one launch programs spanning antivirals, oncology, dermatology and rare diseases.
Generics Bulletin - June 23, 2026
J&J Widens Golimumab Patent Fight With Alvotech Lawsuit
Janssen’s latest suit adds Alvotech to the US golimumab patent fight, threatening AVT05’s planned December approval as biosimilar competition builds around the $1.1bn Simponi franchise.
Generics Bulletin - June 23, 2026
Janssen’s latest suit adds Alvotech to the US golimumab patent fight, threatening AVT05’s planned December approval as biosimilar competition builds around the $1.1bn Simponi franchise.
Generics Bulletin - June 23, 2026
AI Center Stage For Biomed Israel Start-Up Winners 2026
Four innovators, Protai, BAIBYS, caVos Biotherapeutics and Starget Pharma, won Biomed Israel’s 2026 start-up showcase competition.
In Vivo - June 23, 2026
Four innovators, Protai, BAIBYS, caVos Biotherapeutics and Starget Pharma, won Biomed Israel’s 2026 start-up showcase competition.
In Vivo - June 23, 2026
Pharma World Preview 2026: The Formula And Its Fractures
Pharma is generating bigger returns from smaller bets. Evaluate’s World Preview 2026 shows an industry that has found its formula — and is squeezing it hard. The question is how long it holds.
In Vivo - June 23, 2026
Pharma is generating bigger returns from smaller bets. Evaluate’s World Preview 2026 shows an industry that has found its formula — and is squeezing it hard. The question is how long it holds.
In Vivo - June 23, 2026